• Product NameBIIB-021
• Brief DescriptionInhibitors
• Purification99.82%
• Biological ActivityBIIB021 is an orally available, fully synthetic small-molecule inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively. Phase 2.
• Target NameHSP inhibitor
• CAS No. 848695-25-0
• Calculated MW 318.76
• Formulation C14H15ClN6O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:ClC1=C2C(N(CC3=C(C)C(OC)=C(C)C=N3)C=N2)=NC(N)=N1
  Pathways:Cytoskeletal Signaling; Metabolism
  Receptor:HSP90
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 2 mg/mL (6.27 mM); DMSO: 64 mg/mL (200.77 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Lundgren, et al. Molecular Y Therapeutics (2009), 8(4), 921-929.2. Kasibhatla, et al. Journal of Medicinal Chemistry (2007), 50(12), 2767-2778.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting